BioSpace News Archive

Therabest USA. Inc, Therabest Korea and Glycotope GmbH have signed an agreement to assess the clinical development of Therabest’s EiNKTM cell therapy, TB-100, in combination with Glycotope’s immuno-cytokine, GT-00AxIL15 in triple-negative breast cancer patients.

Amphista Therapeutics, a leader in next generation targeted protein degradation approaches, announced a Series B extension investment by the Dementia Discovery Fund.

Calliditas Therapeutics AB announced that they have entered into an exclusive license agreement with Viatris Pharmaceuticals Japan Inc., a subsidiary of Viatris Inc., to register and commercialize Nefecon, a specialty drug recently approved in Europe and the US for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy in Japan.

MRM Health announced that its Type-2 Diabetes Program, developed in collaboration with IFF has achieved preclinical development targets.

Mirum Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for LIVMARLI® oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome two months of age and older.

AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera from AOP Health´s CONTINUATION-PV study and the LOW-PV trial, which is an independent investigator-initiated trial supported by AOP Health presented at ASH 2022 Annual Meeting, New Orleans, USA.

Ascentage Pharma announced that it has released preliminary results from a global Phase II study of lisaftoclax, a key member of the company’s apoptosis-targeting pipeline, as a monotherapy or in combination with CALQUENCE® or rituximab in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, in an oral presentation at the ASH 64th Annual Meeting & Exposition.

Sphere Fluidics announced that it has appointed Richard Hammond as Chief Technical Officer.

Soricimed Biopharma Inc., a clinical stage company focused on the development and commercialization of first-in-class targeted cancer therapeutics, has appointed Dr. Siqing Fu, a North American leader in cancer research, to its Scientific Advisory Board.

Biosion USA, Inc., a global R&D biotechnology company, announced an exploratory research collaboration to create antibody-drug conjugates for the treatment of cancer with ImmunoGen, Inc., a leader in developing next generation ADCs.